Other Clinical Trial - Predictive Value of HAS-BLED & CHA2DS2-Vasc Scores

Status Not yet recruiting

Clinical Trial Summary

To assess the predictive value of two scoring systems, namely HAS-BLED and CHA2DS2-VASc scores, to be linked with bleeding events and recurrence of chest pain and other measures of clinical outcome of percutaneous coronary intervention. The investigators aim to provide evidence for local guidelines of optimum options suited to our population

Clinical Trial Description

Dual-antiplatelet therapy (DAPT) with aspirin and an inhibitor of the platelet P2Y12 receptor is necessary to prevent stent-related thrombotic complications after percutaneous coronary intervention (PCI). (1) Although continuation of DAPT confers substantial and durable benefits that extend beyond the local stented segment, bleeding risk also increases with continued exposure to antiplatelet therapy. (2) Current guidelines give fixed duration of DAPT after coronary intervention but many patients still having early stent thrombosis despite this fixed policy, while others, on the contrary, suffer minor and major bleeding events. These clinical situations should raise the possibility of individualizing therapy. (5) The rationale of this study is to find a new method to tailor the optimal duration of DAPT for each patient by balancing long-term risks for both coronary thrombosis and major bleeding (MB).

The HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly) score has long been used to predict bleeding events in patients on anticoagulation therapy. (3) Also, the CHA2DS2-VASc (congestive heart failure, hypertension, ≥75 years, diabetes, stroke/transient ischemic attack or thromboembolism, vascular disease, elderly, sex) score is a well-established system for prediction of thrombo-embolic events in patients with atrial fibrillation. (4) The aim of the present study is to evaluate the predictive ability of these 2 scoring tools when applied to patients undergoing PCI. ;

Study Design

Related Conditions & MeSH terms

Percutaneous Coronary Intervention

Clinical Trial Details

NCT number	NCT04047199
Study type	Observational
Source	Assiut University
Contact	Mahmoud OS Morsy
Phone	+201008406065
Email	mahmood.osamaa@outlook.com
Status	Not yet recruiting
Phase
Start date	December 1, 2019
Completion date	July 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03959072` - Cardiac Cath Lab Staff Radiation Exposure
Not yet recruiting	`NCT05669222` - The FAVOR V AMI Trial	N/A
Recruiting	`NCT04566497` - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.	N/A
Recruiting	`NCT05240781` - Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk	N/A
Recruiting	`NCT03378934` - Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention	Phase 4
Not yet recruiting	`NCT06025071` - Residual Inflammatory Risk-Guided colcHicine in Elderly Trial	Phase 4
Withdrawn	`NCT04043091` - Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction	N/A
Completed	`NCT02837744` - Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure
Completed	`NCT03085823` - The All-comers Sirolimus-coated Balloon European Registry
Completed	`NCT02044146` - A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk	Phase 2/Phase 3
Completed	`NCT03131271` - Effect of Ice Bag Application to Femoral Region on Pain in Patients Undergoing Percutaneous Coronary Intervention	N/A
Completed	`NCT01135667` - Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI	Phase 4
Completed	`NCT01156571` - A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)	Phase 3
Unknown status	`NCT00751491` - Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)	Phase 3
Completed	`NCT00725868` - Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention	N/A
Completed	`NCT03708588` - Chewed Versus Integral Pill of Ticagrelor	Phase 4
Completed	`NCT04163393` - R-One Efficiency For PCI Evolution With Robotic Assistance	N/A
Recruiting	`NCT05554588` - Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI	N/A
Recruiting	`NCT06080919` - Plaque Modification And Impact On Microcirculatory Territory After Drug-Coated Balloon Percutaneous Coronary Intervention (PLAMI).	N/A
Recruiting	`NCT05353140` - LAAO Versus NOAC in Patients With AF and PCI	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Predictive Value of HAS-BLED and CHA2DS2-Vasc Scores After PCI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms